Physician profile
Imad Omer
NPI 1356318059
$21,544.43
in general payments reported to CMS, 2019-2025
30 companies · $1,034 in 2025
The $1,034 reported for 2025 was more than what 79% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,635 · 2020: $1,658 · 2021: $1,579 · 2022: $1,909 · 2023: $1,500 · 2024: $11K · 2025: $1,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,208 · Food and Beverage: $4,045 · Travel and Lodging: $1,510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,207.50 |
| Food and Beverage | $4,045.19 |
| Travel and Lodging | $1,509.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $10,366.71 | 2023-2024 | |
| Gilead Sciences, INC. | $1,801.19 | 2019-2025 | Biktarvy |
| Abbvie INC. | $1,248.42 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,125.91 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Insmed, INC. | $1,113.15 | 2019-2025 | Arikayce, Brinsupri |
| Viiv Healthcare Company | $801.64 | 2019-2025 | Dovato, Rukobia, Cabenuva |
| Astellas Pharma US INC | $652.88 | 2019-2025 | Cresemba |
| Cumberland Pharmaceuticals, INC. | $575.56 | 2019-2022 | |
| La Jolla Pharmaceutical Company | $545.86 | 2020-2025 | Xacduro, Xerava |
| Cipla USA INC. | $495.43 | 2019 | |
| Allergan, INC. | $363.78 | 2019-2020 | |
| Pfizer INC. | $337.37 | 2019-2025 | |
| Theratechnologies INC. | $287.71 | 2019-2023 | Egrifta, Trogarzo |
| Triad Life Sciences INC. | $285.32 | 2022 | |
| Tetraphase Pharmaceuticals, INC. | $282.37 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $233.03 | 2019-2025 | Rezzayo, Kimyrsa, Vabomere |
| Mayne Pharma Commercial LLC | $193.51 | 2019-2021 | |
| Janssen Biotech, INC. | $187.97 | 2019-2023 | Symtuza |
| Shionogi INC | $155.48 | 2021-2023 | Fetroja |
| Ferring Pharmaceuticals INC. | $106.31 | 2022-2023 | Rebyota |
| Biotissue Holdings INC. | $88.62 | 2023 | |
| Paratek Pharmaceuticals, INC. | $70.40 | 2019-2024 | Nuzyra |
| Vyera Pharmaceuticals, LLC | $50.43 | 2019-2020 | |
| Csl Behring | $38.61 | 2019-2023 | Hizentra |
| Abiomed | $35.46 | 2025 | |
| Emd Serono, INC. | $34.87 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.98 | 2023 | Livtencity |
| Grifols USA, LLC | $14.87 | 2021 | |
| Kci USA, INC. | $14.39 | 2019 | |
| Medela LLC | $13.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imad Omer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.